%0 English Abstract
%T [Use of anti-IL-1 drugs during pregnancy].
%A Faure-Bardon V
%A Beghin D
%A Latour M
%A Coulm B
%A Vauzelle C
%A Elefant E
%A Marin B
%J Gynecol Obstet Fertil Senol
%V 0
%N 0
%D 2024 Apr 16
%M 38621625
%F 1.058
%R 10.1016/j.gofs.2024.04.004
%X Anti-Interleukin-1 (Anti-IL-1) drugs are used to treat some chronic rheumatic diseases that can affect young people, including women of childbearing age. Two anti-IL-1 drugs are available in France: anakinra and canakinumab. Data on their use during pregnancy are still limited. Based on the published literature, we carried out a review of the use of these anti-IL-1 therapies during pregnancy: therapeutic indications, pharmacological profiles and assessment of embryonic, fetal and neonatal risks. Based on this analysis, and given the absence of any reported concern, it is possible to consider the use of these two treatments during pregnancy if the clinical situation so requires and under certain conditions. Based on the data available to date, anakinra should be preferred to canakinumab whenever possible.